New light-activated diabetes drugs will be available
April 20, 2016 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, in a research paper published in the international magazine Angewandte Chemie International Edition , researchers from the University of Birmingham developed a new type of light-activating tool through which researchers can reveal how the drug adapts and begins to resist. Type 2 diabetes, this study provides a new way to develop a new generation of anti-diabetic drugs that are activated by blue or ultraviolet light.
Researcher David Hodson said that the current treatment for type 2 diabetes depends mainly on dietary and drug interventions to restore the body's ability to release insulin. In the past 10 years, Lilly and Amylin Pharmaceuticals jointly developed the first approved type 2 The diabetes drug intestine hypoglycemic analog, a drug that mimics incretin mimetics, has revolutionized the treatment of type 2 diabetes.
The challenge for scientists today is how to make these interventions more targeted. By improving understanding of cellular receptors, researchers can design drugs that are more efficient and have fewer side effects; light activation technology can help change The shape of the drug provides a certain idea for the development of new diabetes therapies. Current drugs primarily target the glucagon-like peptide 1 receptor (GLP-1 receptor), which is a G-protein coupled receptor, but the researchers are not aware of the mechanism of action of this receptor. This limits the development of safe and effective drugs in the later period.
The GLP-1 receptor has a special allosteric site, which is the focus of scientists developing drugs with excellent selectivity. However, researchers lack the tools to reveal the mode of action and mechanism of the allosteric site; To overcome this problem, the researcher Professor Dirk Trauner and his colleagues combined synthetic chemistry, biology and high-throughput screening techniques to develop a new anti-diabetic drug that can be controlled by light.
The new drug, called PhotoETP, can be adapted to adapt to the allosteric site of the GLP-1 receptor, but it can amplify the activation signal and insulin release effects; based on the above studies, the researchers say that a new generation The light activates anti-diabetic drugs or will come out to effectively control the blood sugar of the patient's body with fewer side effects.
Type 2 diabetes currently affects approximately 10% of adults. Patients who are unable to produce adequate amounts of insulin will eventually lead to elevated blood glucose levels and other symptoms of the disease. This study may bring significant changes to the treatment of diabetic patients. .
Direct Seeding Machine,Direct Paddy Seeder Machine,Direct Rice Seeding Machine,Paddy Direct Seeding Machine
Taizhou Yingtian Agricultural Machinery Manufacturing Co., Ltd. , https://www.sakuradaagc.com